Commonwealth of Kentucky launches groundbreaking initiative to test its health care workers for immunity and establish nation’s top plasma donor pool

Commonwealth of Kentucky launches groundbreaking initiative to test its health care workers for immunity and establish nation’s top plasma donor pool


The Commonwealth of Kentucky, in collaboration with the University of Louisville Christina Lee Brown Envirome Institute and the Louisville Healthcare CEO Council, is launching a groundbreaking initiative with three large Kentucky hospital systems; Baptist Health, Norton Healthcare and UofL Health. The purpose is to help its health care workers understand whether they were unknowingly exposed to COVID-19, to determine how much immunity was generated by such exposure, and to identify those with the best immune responses as donors of high-quality plasma for rescue treatment of patients with advanced COVID-19. In addition, these data will be informative as scientists worldwide are working to determine whether quantitative antibody measurements can be used to predict immunity in the overall workforce. This program represents a unique alliance between government and otherwise competing private groups in order to address an unprecedented crisis.

Testing will begin with high-risk personnel in Kentucky, starting with the health care workforce. As the process is scaled up it will be made available to other essential workers. There will be three steps of testing. First, a point-of-care test will provide a yes or no answer on the presence of antibodies. In a second step, positive blood will then be assayed for the amount of antibodies present in the blood. Finally, in patients with high amounts, the neutralizing power of the antibodies will be evaluated.

The University of Louisville Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), has established a high-throughput real-time assay for SARS-CoV-2 antibodies that will be utilized and CPM will use their renowned Bio Safety Level 3 facility to test for the neutralizing activity of the antibodies.

“The University of Louisville is committed to addressing all forms of health,” said Neeli Bendapudi, President of the University of Louisville. “We are uniquely positioned to play a key role in this effort because of our talented researchers at CPM and our UofL Regional Biocontainment Laboratory which allows us to establish the very best donors of plasma for patients.”

This unprecedented collaboration of the public and private sector has already secured private donations of $1.75 million in the form of a challenge grant to build community-wide coalition of philanthropic support, which will allow the program to scale more quickly and save more lives. (Click here for more details on how you can help.)

“America and Louisville need more and advanced COVID-19 testing now. I am excited about this ambitious project and its potential to provide useful data for the recovery of our community. Louisville's team of cutting-edge scientists represents the best of who we are as Louisvillians, compassionate, smart and entrepreneurial,” said Louisville Mayor Greg Fischer.

“This is exactly the kind of collaboration that Kentucky is poised to enable,” said Dr. Cedric Francois, CEO of Apellis Pharmaceuticals and LHCC board member. “We have the infrastructure in our commonwealth to quickly bring this revolutionary technology together by leveraging the great work already being done with the health care stakeholders, such as Norton Healthcare’s convalescent plasma program and the extensive work that had already been done to start their antibody serology testing, to improve Kentucky’s response and recovery to the COVID-19 pandemic and be a model for the rest of the nation.”

“This model for testing is exciting and it is our hope that antibody measurements can be used to predict immunity,” said Gov. Andy Beshear. “If so, it will be a critical tool in the reopening of Kentucky’s economy.”

Learn more about the program, named the Co-Immunity Project, here.

Can we be friends? Bacteria causing Legionnaire’s disease is just trying to find a home in human lungs

UofL researchers find mechanism used by Legionella pneumophila allows coexistence in amoeba but results in pneumonia and inflammation in humans
Can we be friends? Bacteria causing Legionnaire’s disease is just trying to find a home in human lungs

Fountains can aerosolize water containing bacteria that cause Legionnaire's disease

Microbiologists at the University of Louisville have found that Legionella pneumophila usesa “tool” that allows it to thrive in an amoeba host and in human lung cells, but with very different results. In the amoeba, considered the bacterium’s natural host, it results in coexistence, making the amoeba host a suitable, safe home for the bacteria’s proliferation. In the human, however, it leads to a deadly form of pneumonia and a paradoxical inflammatory response in the lungs.

In an article published last week in Cell Host & Microbe, Yousef Abu Kwaik, Ph.D., professor, and Chris Price, Ph.D., senior research scientist, both of the Department of Microbiology and Immunology, and other researchers at the University of Louisville, explain that L. pneumophila uses the same mechanism or virulence determinant in both amoeba and the accidental human host, but with different results. A virulence determinant is a gene or protein that plays a key role in disease development.

Legionnaire’s disease is a type of pneumonia caused by the bacterium L. pneumonphila. Legionnaire’s disease, named for one of the first documented outbreaks of the infection at an American Legion convention in Philadelphia in 1976, accounts for approximately 15 percent of pneumonia cases worldwide and has a mortality rate of 20 to 50 percent. L. pneumophila evolved as an environmental bacteria that lives in water, surviving and proliferating in several species of amoeba as its natural hosts. It is the only bacterial pathogen for which amoeba are the natural hosts and humans are accidental hosts.

The bacteria are transmitted to humans who accidentally inhale them in water particles that have been aerosolized by man-made devices such as cooling towers, whirlpools, fountains or misters such as those used in grocery stores or in water parks. These devices distribute the water particles into the air along with bacteria that may be present in the water.

When L. pneumophila enters its natural amoeba host, it injects a protein into the single-celled organism that prevents the amoeba from destroying the bacteria and provides a safe home in which the bacteria may grow and spread. When L. pneumophila enters human lungs, it injects the same protein into alveolar macrophages. Contrary to the outcomes in the amoeba, the bacterial protein stimulates an inflammatory response in human macrophages that contributes to pneumonia. This effect is counterproductive to the bacteria as it stimulates the human host to restrict the invading bacteria. The effect of the injected protein in human cells also contradicts evolutionary co-existence of the pathogen with the human host, which is considered an accidental host. The injected bacterial protein has evolved in Legionella to interfere with a specific process in the amoeba host that does not exist in the more evolved human cells, where a paradoxical effect is mounted in response. 

“Our findings show for the first time that a bacterial ‘tool’ has evolved exclusively to manipulate an amoeba host-specific process, but it has a paradoxical effect on the human host,” Abu Kwaik said.

This knowledge may lead to methods that help reduce the bacteria’s ability to survive in amoeba in water sources, limiting the transmission of Legionnaire’s disease.

“Since the bacteria are not transmitted from one person to another, we have the opportunity to prevent transmission by targeting the bacterial protein with small molecule inhibitors,” Abu Kwaik said. “That would enable the amoeba to restrict and degrade the bacteria, blocking their amplification in the water system and, in turn, abolishing accidental droplet transmission to humans.”


April 14, 2020

UofL researchers describe possible mechanism for link between obesity and breast cancer

It is widely accepted that higher levels of body fat increase the risk of developing breast cancer, as well as other cancers. Based on his ongoing research, Bing Li, Ph.D., associate professor in the Department of Microbiology and Immunology and UofL Health - James Graham Brown Cancer Center, has published an article which proposes a unique theory that a protein secreted by fat cells drives the development of breast cancer.
UofL researchers describe possible mechanism for link between obesity and breast cancer

High expression of adipose fatty acid binding protein (FABP4) in mammary glands, shown in red, promotes obesity-associated breast cancer development


Li has been conducting research funded by the National Cancer Institute for the past five years which led him to the connection between activity of a protein expressed in fatty tissue and an increase in breast cancer development. Li and colleagues shared the theory in an invited forum in Trends in Molecular Medicine, a Cell Press journal, published online last week. The article describes Li’s theory that adipose fatty acid binding protein (FABP4), expressed in fatty tissue, is responsible for fueling breast cancer tumor growth.

“Many types of cancer are related to obesity, not only breast cancer. More than 13 types of cancer are clearly associated with obesity and I think the list will go on and on once we have more data,” Li said. “In our research, we found the fatty acid binding protein family, especially one member, FABP4, plays a very critical role in the association of obesity and cancer, most specifically breast cancer. We theorize that FABP4 is responsible for the underlying molecular mechanism which promotes obesity-associated breast cancer development.”

Adipose tissue in the body produces FABP4 within fat cells, where it processes and distributes water-insoluble long-chain fatty acids. A certain amount of FABP4 enters the bloodstream under normal conditions. However, as a higher volume of fat tissue is accumulated, more FABP4 is secreted into circulation.

“When we get obese, this protein is secreted out much more into the circulatory system,” Li said. “Normally these molecules are inside the cells, but when people are obese, the molecules are outside.”

Li’s theory offers two ways in which FABP4 may stimulate growth in breast cancer tumors.

First, within the cells, FABP4 increases in certain tumor-associated macrophages, which accumulate in tumors to promote tumor growth. Li’s research also revealed that when FABP4 is inhibited, tumor growth is reduced in animal models even though the adipose tissue remained.

Second, when elevated levels of FABP4 circulate outside the fat cells in obesity, the protein promotes breast cancer development through direct interaction with breast cancer cells. In animal research, mammary tumor development and growth were reduced in obese animals in which FABP4 was controlled.

In addition, FABP4 in the bloodstream appears to work in multiple mechanisms to fuel interactions between tumor components and fat cells, thereby promoting cancer development.

Moreover, Li’s research group recently published findings in Cancer Research showing that different types of high-fat diets have different effects on tumor development. High-fat diets of either cocoa butter or fish oil both result in fat-induced obesity. However, the cocoa butter diet results in increased mammary tumor growth, while the fish oil diet does not. This study not only confirms the critical role of FABP4 in obesity-associated cancer, but reveals that not all obesity promotes the development of tumors.

Li and his team believe a better understanding of how FABP4 works both within macrophages and in circulation could provide opportunities to prevent certain breast cancers from progressing. It may also lead to the development of treatment methods that target FABP4 with drugs or specific antibodies.

“Now we are trying to generate some antibodies for this protein, which could be a very effective therapy strategy for obesity-associated cancer,” Li said.


April 13, 2020

UofL faculty member provides insight on importance of strengthening mental health in time of physical isolation and uncertainty

UofL faculty member provides insight on importance of strengthening mental health in time of physical isolation and uncertainty

Joe D'Ambrosio, PhD

Physical isolation and social distancing have become the new normal amid the COVID-19 pandemic, and strengthening psychological coping is as important as staying physically well. 

“One of the big challenges I see in my clients is the inability to deal with uncertainty. The lack of control over this disease has confronted so many with what little power we have over our lives,” said University of Louisville Trager Institute and Republic Bank Foundation Optimal Aging Clinic Director of Wellness Joseph G. D’Ambrosio, PhD, JD, LMFT, CSW.

D’Ambrosio, who also is an assistant professor in the UofL School of Medicine, says having an understanding of the disease is needed in order to protect ourselves and others, but it also is important to remember “this, too, shall pass, and we will be stronger because of it. Past generations have risen up and used crisis situations to improve the world, and we can do the same.”

He points out that a crisis can present an opportunity to stop and re-evaluate life.

“I find that in times like this, it is important to look introspectively at who we are and how we want to truly live. So many of us live a life that was prescribed by either family, society or our own beliefs about what we should do to be successful – but it may not be allowing us to be as happy or as prosperous as we could, if we were doing what we really wanted,” he said.

He gives advice on jump-starting mental strength that can lead individuals to the future life they truly want:

  • Start a mindfulness practice. Begin by committing to five minutes in the morning and five minutes at night to silence and contemplation. Increase the time commitment daily so that you are doing at least 20 minutes twice a day. It will help situate you in the world where you can be your best self. There are many free apps such as Insight Timer or Calm that can help. 
  • Now is a good time to begin to live a healthy lifestyle. For many that means changing diet to include more fruits and vegetables, and eating less meat and dairy. Work hard to make your body as immune proof as it can be, D’Ambrosio said. 
  • Most importantly, have compassion for yourself and those around you. “We forget what a little bit of shared love can do to change ourselves and the world,” D’Ambrosio said.

Parents: Routines give children a sense of safety and security

Children are among those most affected by the new normal, D’Ambrosio said, and when a child experiences uncertainty it increases stress and feeling of helplessness. 

“A young child’s brain undergoes constant development as they grow. Routines help the part of a young child’s brain that is able to plan ahead and make predictions about the future. Having routines in place give children the space to feel good about themselves as they know what is coming, and understand that they can accomplish the tasks presented,” he said.

D’Ambrosio encourages parents not to be too rigid if they go off schedule, just confirm that tomorrow you are back on schedule. 

“Be kind to yourself and your children. These are stressful times and flexibility may be your biggest ally,” he said. 

He offers some important tips for making day-to-day life at home more enjoyable and manageable for both children and parents:

  • Plan a specific time to awake and go to bed, do schoolwork, perform house chores, play, eat, exercise and have family time.
  • Develop a specific time for children to spend by themselves either drawing or reading.
  • Create a bedtime ritual, if you don’t already have one.
  • Work with your children to make pictures or signs for each activity that they can see and count on happening.
  • Be sure to let children know when the next routine is going to happen so that they can be prepared. For example, “we have 15 minutes left of study time so that we can take an exercise break.”
  • Use a dry-erase board or poster to post a daily agenda that includes reading time, playtime, naps, etc.
  • Assign chores to your children. Even children as young as 3 years old enjoy sharing adult responsibilities.
  • When preparing meals, include children in the preparation even if it is something small.
  • Encourage video-chatting with family and friends. Two children drawing together while on a video-chat can be fun and give the children a chance to connect.
  • Help your children to become artists by using old magazines, wrapping paper and mail advertisements to make collages.
  • Encourage independent childhood play time. Parents don’t have to be with kids 24/7,   and the separation is a great way to help children differentiate from their parents. That is a skill they will need to get through the rest of their lives, D’Ambrosio said.

Read a Q&A with D’Ambrosio on mental health insights during the COVID-19 pandemic on the UofL Trager Institute blog.

Dr. Matt Cave's cutting edge research on Exploring the Role of Environmental Chemicals in Liver Disease

Dr. Matt Cave (UofL GI; Hepatobiology & Toxicology COBRE Core Leader) does cutting edge research on Exploring the Role of Environmental Chemicals in Liver Disease. His research is featured on the NIEHS website:

UofL has been a leader in the area of environmental hepatology since the 1970s.

UofL researchers seek new drugs to fight coronavirus using computers in schools across Kentucky using DataseamGrid

UofL researchers seek new drugs to fight coronavirus using computers in schools across Kentucky using DataseamGrid

The 3-D structure of the main protease for SARS-CoV-2.

The novel coronavirus may have K-12 students in Kentucky’s school districts learning at home, but researchers at the University of Louisville are using the computing power of thousands of computers in classrooms across the state to identify drugs to treat COVID-19. The desktop computers are part of the DataseamGrid, a network of computers housed in classrooms of 48 Kentucky school districts as part of a partnership designed to support research, education and workforce development.

John Trent, Ph.D., deputy director of basic and translational research at the UofL Health - James Graham Brown Cancer Center and Wendell Cherry Endowed Chair for Cancer Translational Research, conducts virtual screening to discover new cancer drugs using the DataseamGrid for high-volume computations. Today, he has the computers at work 24/7 to identify the most promising drugs and compounds to fight SARS-CoV-2 and its disease, COVID-19.

“In these unprecedented times, we had a resource where we could potentially make an impact quickly and switch over from some of our cancer targets to SARS-CoV-2 targets,” Trent said. “We have been very successful in doing this in cancer for 15 years. We are using the same approach in targeting the coronavirus, just targeting a different protein.”

Established in 2003, Dataseam is funded by the Kentucky General Assembly to provide computing infrastructure, workforce development and educational opportunities for students and staff in Kentucky school districts. Available computing power in those units is put to work performing computer modeling calculations to screen anti-cancer drugs for Trent’s team and collaborators at UofL.

“Like a lot of industries, we have shifted our skills and infrastructure to address this issue,” said Brian Gupton, CEO of Dataseam. “We are always going to have cancer, but at least for the time being, we are glad the DataseamGrid is here for Dr. Trent to screen those drugs.”

In mid-March, Trent and his team entered new data onto the DataseamGrid, along with UofL’s dedicated research computers, in a two-pronged approach to match three-dimensional models of proteins in SARS-CoV-2 to drugs and compounds that could help in treating or preventing COVID-19. The DataseamGrid provides up to 80 percent of the computational power for these projects.

The first approach is to test about 2,000 drugs already on the market and another 9,000 investigational drugs and nutraceuticals that have been tested for toxicity to isolate those most likely to be effective against the virus.

“For the immediate approach, we are testing drugs that already are approved by the FDA or have been tested in humans. If we find activity with those drugs, we could get them into patient trials a lot quicker,” Trent said. “However, these drugs obviously were designed for something else and they may not have the same efficacy of a very selective drug.”

To find that selective drug, Trent’s second prong of research includes computational models to screen 37 million small molecules and compounds against the target proteins in SARS-CoV-2. These molecules could be used to develop a new drug specifically to treat the virus. That process would take more time, however, to obtain FDA approval.

“That initial discovery of a new, more-selective agent is more long term. You are looking at 12 to 18 months before you would even think about testing those in a patient,” Trent said. “But time is of essence at the moment, so we are doing both things at the same time.”

Using the DataseamGrid and UofL research computers, Trent and his team are screening the drugs and small molecules against 3-D structures of four proteins in the virus to see which compounds might bind with the proteins. A drug that interferes with the activity of any of these proteins would reduce the virus’s ability to spread.

Trent began the research with the first two proteins described for SARS-CoV-2: the main protease, an essential enzyme used by the virus to break down viral proteins and make new virus particles, and spike proteins, the triangular “knobs” the virus uses to attach itself to host cells. These spikes are the knobs commonly seen in graphic images on the surface of the virus. Trent now also is testing drugs against two additional target proteins that were described very recently.

So far, the process has identified about 30 drugs as potentially effective against SARS-CoV-2. Trent recommended these for biological testing by other UofL researchers in the UofL Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM). Directed by Kenneth Palmer, Ph.D., the CPM is one of only a few labs in the United States capable of testing the drugs against the virus. That testing is expected to begin in mid-April.

If the CPM researchers find the drugs to be effective against SARS-CoV-2 in the lab, they could be moved to the next phase of testing in animal models, testing that also may be conducted at CPM.

“This computer modeling is an excellent way to identify the best potential candidates for laboratory testing rapidly, and this strategy could lead to relief sooner rather than later for patients suffering from COVID-19,” Palmer said.

Gupton says it is good to know the DataseamGrid continues to support urgent medical research even though students are working from home.

“Ironically, we hope to return to cancer research as soon as possible,” Gupton said. “Even though the students are not in classrooms, Kentucky school districts are providing them with instruction, technology, internet access and even meals. The districts’ Dataseam systems engineers are supporting both the university’s work and K-12 efforts. We all are proud to be ‘digital first responders’ in Kentucky’s part of the global fight.”

As part of the Dataseam partnership, UofL provides academic scholarships annually for students from participating school districts who come to the university to pursue a degree in science, technology, engineering or math.



April 9, 2020

UofL names Ganzel vice president, announces UofL Health Board

UofL names Ganzel vice president, announces UofL Health Board

UofL's dean of the School of Medicine, Toni Ganzel, MD, MBA, also has been named vice president for academic medical affairs.

The University of Louisville and UofL Health have announced significant leadership appointments.

Toni Ganzel, M.D., dean of the UofL School of Medicine, has received an additional appointment as vice president for academic medical affairs. Reporting to President Neeli Bendapudi and Provost Beth A. Boehm, Ganzel will oversee research activity at the Health Sciences Center, including the centers and institutes. In addition, she will oversee areas including diversity and inclusion, faculty development and student health.

She will work closely with UofL Health CEO Tom Miller to ensure successful teaching and research at the recently expanded UofL Health network.

“Dr. Ganzel has done an excellent job as dean of the School of Medicine,” said UofL President Neeli Bendapudi. “I value her expertise and her leadership and look forward to continuing to work with her in this new role. She and Tom Miller are a great team to lead medical education, research and care in our community.”

Bendapudi and Ganzel will join nine other individuals from a variety of disciplines on the newly formed UofL Health Board of Directors. The board members from the university are:

  • Neeli Bendapudi, UofL president
  • Toni Ganzel, dean, School of Medicine, and vice president for academic medical affairs
  • Kelly McMasters, chair, Department of Surgery
  • Diane Medley, member, UofL Board of Trustees
  • Fred Williams, physician, UofL Health

Community members include:

  • Pat Mulloy, of counsel, Wyatt, Tarrant and Combs
  • Ben Breier, CEO, Kindred Health care
  • Heidi Margulis, retired chief corporate affairs officer, Humana
  • Junior Bridgeman, CEO, Bridgeman Hospitality
  • William Ballard, attorney and former health care executive
  • T. Richard Riney, former executive vice president, CAO of Ventas

“These board members understand the complexities of today’s health care climate and will deliver a vision for the future,” Bendapudi said. “The foundation for UofL Health is strong. This board, along with the continued support of our elected officials in Frankfort, ensures our ability to deliver excellence, innovation and compassionate care for all in the Commonwealth.”

Key to novel coronavirus therapeutics could be grown in … tobacco?

UofL’s nationally networked lab enables researchers to safely study virus
Key to novel coronavirus therapeutics could be grown in … tobacco?

UofL is home to one of 12 Regional Biocontainment Laboratories and two National Biocontainment Laboratories in the United States.

A decade ago, when the National Institutes of Health needed to place a high-security biocontainment laboratory in Kentucky, capable of safely studying dangerous and emerging infectious diseases, they turned to the University of Louisville.

Over the past decade, the laboratory has responded to national emergencies, studying highly infectious diseases such as SARS and others. Today it is being called upon in research efforts focusing on the novel coronavirus, SARS-CoV-2, and the disease it causes, COVID-19. And in that lab, researchers are exploring compounds that hold promise as therapeutic agents against the disease and could be grown quickly in host tobacco plants.

That’s right, tobacco.

A strain of the reviled plant that has caused fatal diseases for centuries could be the key to quickly mass-producing a preventive agent, treatment or vaccine for COVID-19.

“A protein in the university’s own proprietary portfolio and other compounds from industry sources may be useful against SARS-CoV-2,” said Kenneth Palmer, Ph.D., director of UofL’s Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM).  “We are currently conducting laboratory research with these compounds that could eventually lead to a therapeutic agent against COVID-19.”

UofL’s Regional Biocontainment Laboratory (RBL) is housed in the CPM and is part of a network of 12 regional and two national labs nationwide that were established with support from the NIH to conduct research with infectious agents. The national labs are located at Boston University and at the University of Texas Medical Branch at Galveston. Regional labs are located at the University of Chicago, Duke University, Boston University and other universities throughout the U.S. The RBL network stands ready in response to public health emergencies and emerging diseases such as the novel coronavirus.

The UofL RBL includes Biosafety Level 3 facilities built to the most exacting federal safety and security standards. The stringently secure facilities protect researchers and the public from exposure to the pathogens being investigated. As part of the RBL network, the UofL RBL is able to respond to needs of researchers, federal agencies and pharmaceutical companies nationwide to conduct research with infectious agents.

Palmer and his research team received samples of SARS-CoV-2 last month and are researching it only in the highly secure confines of the RBL. Covered head to toe in personal protective equipment to prevent self-infection, the researchers now are testing the therapeutic candidates against the disease in cell cultures.

The UofL compound is known as Q-Griffithsin and is co-owned by the university with the National Cancer Institute and the University of Pittsburgh. It is a potent anti-viral protein that possesses microbicidal capabilities. The other compounds are proprietary to their respective companies.

The research goal is to identify the best potential treatment option that could eventually be tested in humans, first at UofL to gauge its safety and efficacy and then later at the University of Pittsburgh and other clinical trial sites to continue to test its effectiveness. Although there are no guarantees, “we believe we could move into human clinical trials by the end of the year,” Palmer said.

That’s where the tobacco plants come in. A large amount of the ultimate therapeutic will be needed for human trials. Kentucky’s historical cash crop is a perfect host to produce the quantities needed.

“The unique quality about studying these compounds in Kentucky is that we can rapidly scale up production of tobacco plants to produce the large amounts of the agent we will need for human testing,” Palmer said. “As people already know, tobacco grows very well in Kentucky.”

Some of the compounds are already showing promise in the laboratory. While the end of the year seems far off in the current coronavirus climate, it is realistic because “SARS-CoV-2 may be with us for a couple of winter seasons. We’d like to have a product that could be tested if the infection comes back in the cold season like influenza does,” Palmer said.

If it does, Palmer and his team will be ready. “We think we will be able to deliver the drug as a nasal spray and hope we can use it as a preventive, pre-exposure treatment before a vaccine could be developed. This will be important for the public and especially for those who are at risk because of their age or pre-existing health conditions or because they work in health care.”

UofL Health expedites telehealth expansion in response to COVID-19 pandemic

UofL Health is launching an immediate expansion of its telehealth program to improve patient access with more than 600 of our providers, while maintaining social distancing, during the ongoing COVID-19 pandemic.

On March 25, Kentucky Gov. Andy Beshear emphasized the importance of using this technology, especially in our current environment.

“This is something that had been on track for a launch later this year,” said Wade Mitzel, Chief Operating Officer, UofL Physicians. “But given the current need to reduce contact and increase precaution, we fast tracked the launch in order to give our patients peace of mind, with a convenient and safe way to access their provider.”

UofL Health – Telehealth will be available to established and qualifying new patients by calling our primary care access line: 502-588-4343. A scheduling specialist will help determine whether a telehealth or in-person visit would best serve the need.

Our telehealh appointment is like an in-person appointment with a provider. During the visit you’ll talk about your current health concerns and learn what to do.

  • Your visit can take place from a location that is the most convenient for you.
  • Your provider will use a video-based application to talk with you by phone, tablet or computer.
  • Our telemedicine platform is secure and HIPAA compliant.
  • Your photo and voice will not be recorded or stored.
  • Your privacy and rights will be respected and ensured.

If a telehealth appointment is appropriate, the scheduler will provide further instructions on downloading the application, verify an email address and confirm that you have a webcam or built-in camera for your desktop, laptop, phone, tablet or other compatible device. When it is time for your appointment to begin, you’ll click on a link to be connected with a provider.

Through UofL Health – Telehealth our providers can provide an initial assessment of symptoms related to COVID-19, plus treat common conditions like colds and flu, sore throats, rashes, allergies, bladder infections and more. Providers may prescribe medications, if appropriate, recommend an over-the-counter medication or provide home care options. If needed, the provider may refer patients to an appropriate UofL Physicians - Primary Care office location, specialist or to an emergency department.

COVID-19 can't stop another successful Match Day for UofL internal medicine residency programs

Minus the usual festivities, Match Day 2020 brings another solid incoming class for the UofL Internal Medicine, Combined Med-Peds residency groups
COVID-19 can't stop another successful Match Day for UofL internal medicine residency programs

University of Louisville medical students celebrate Match Day in 2019

Although it didn't take place in the usual manner due to the global COVID-19 pandemic, University of Louisville medical students, and others nationwide, still enjoyed the thrill and excitement of finding out their future paths in medical education.

Match Day forged ahead on March 20, as prospective medical residents opened their envelopes from the National Residency Match Program to find where they had been matched for their future training as residents.

"I would like to welcome 24 categorical, 16 prelim, and five med-peds interns to our residency program!" Jennifer Koch, M.D., FACP, Director of the UofL Internal Medicine Residency Program said. "As our healthcare system deals with the current COVID-19 crisis, it reminds us how fortunate we are to have such a diverse and dedicated group of young physicians who will be training in our program beginning in July."

In addition, the Combined Internal Medicine-Pediatrics Residency Program, under the direction of Laura Workman, M.D., FAAP, FACP, brought in yet another solid class.

"We are so thrilled with our class of incoming residents," Workman said. "They are a wonderful group and we are proud to have them as part of our med-peds family. We look forward to them starting this summer!"

Conducted annually by the NRMP, The Match uses a computerized algorithm designed to the best results by aligning the preferences of applicants with the preferences of residency programs. The results are used to fill thousands of training positions available in the United States.

Our incoming Class of 2020 includes:

Categorical Residents

  • Anuja Abhyankar - Grant Government Medical College
  • Apurv Agarwal - Maulana Azad Medical College
  • Jillian Berger - Indiana University
  • Brandon Busch - University of Mississippi
  • Mary Casey - University of Louisville
  • Saiteja Chava - Saint Louis University
  • Garvit Chhabra - Maulana Azad Medical College
  • Claire Crawford - University of Louisville
  • Quan Do - University of Louisville
  • Zainab Farooqui - University of Pikeville
  • Dylan Flaherty - Philadelphia College of Osteopathic Medicine
  • Natasha Fraser - University of Louisville
  • Martha Gallegos - University of New Mexico
  • Nicole Giddens - University of Queensland
  • Brian Goodman - University of Pikeville
  • Mouaz Haffar - West Virginia University
  • Michael Hogg - University of Louisville
  • Nolan Interial - Lincoln Memorial University
  • Jaewon Jung - Indiana University
  • Neha Nidhi - The Ohio State University
  • Pranav Pillai - Topiwala National Medical College
  • Manasa Sagaram - Arizona College of Osteopathic Medicine
  • Marianna Weaver - Liberty University
  • David Wilhelm - Lake Erie College of Osteopathic Medicine


Preliminary Residents

  • Simra Ahmed - University of Louisville
  • Christopher Atkins - Marshall University
  • Brennan Boyd - University of Arizona
  • Abigail Hatfield - University of Pikeville
  • Daniel Holbrook - University of Louisville
  • Joshua Iltis - University of Texas San Antonio
  • Timothy Mahanes - University of Louisville
  • Ashlee Margheim - University of Louisville
  • Chelsea-Ann Patrey - Medical University of South Carolina
  • Sina Rashidi - Albert Einstein College of Medicine
  • Scott Ray - Des Moines College of Osteopathic Medicine
  • Jasmine Robinson - University of Louisville
  • Amy Shah - University of Missouri-Kansas City
  • Shannon Strader - Lincoln Memorial University
  • Andrew Villasenor - Lincoln Memorial University
  • Yi Zhang - Marian College of Osteopathic Medicine


Combined Med-Peds Residents

  • Molly Bedenbaugh - Medical University of South Carolina
  • Hannah Frudden - University of Illinois
  • Joseph McHale - University of Queensland
  • Malik McMullin - University of South Alabama
  • Anna Nelson - West Virginia School of Osteopathic Medicine

HSC Contingency Plans

Dear Colleagues:

This email is a follow up to the EVPRI’s email concerning COVID19 preparedness for the research community. Much of this email contains instructions to prepare our laboratories for the immediate future in case COVID19 causes significant disruptions in daily university operations. Most of the recommendations are for basic research laboratories. I’m asking departmental chairs and center directors to communicate these recommendations to their faculty and laboratory managers.


  1. Establish a clear communication plan for each laboratory – Assemble a laboratory directory with cell phone numbers, land line numbers and email addresses. Develop a communication plan for email and phone text messaging and test it. Personnel must have the ability to contact other staff and faculty so they can receive instruction about laboratory issues. I ask that Chairs and Center directors forward all completed laboratory directories to me and the EVPRI by Tuesday March 17th.


  1. Designate 1 to 2 essential personnel in each laboratory – In the event that a major disruption in university function occurs, it is important that each laboratory identify these key personnel so that they can be given access to the facilities. Laboratory essential personnel should be prepared in the coming week to keep the laboratory functioning. Some tasks to consider are reagent preservation, maintenance of long-term experiments, monitoring of essential reagent storage equipment, monitoring of sensitive equipment and human subject issues. I ask that Chairs and Center directors forward a list of key personnel sorted by laboratory to me and the EVPRI by Tuesday March 17th.


  1. Develop a clear plan to shut down your laboratory – If the university is closed for any period of time it is important to consider the effects this will have and the actions that must be completed to ensure safety. These actions include: preserve research projects and critical reagents, protect sensitive equipment, ensure safety of an unattended laboratory, preserve data integrity, among others. Laboratory leaders should identify any experiments that can be ramped down or delayed. Faculty should identify others who do similar research to identify ways to work together to maintain critical laboratory functions and to share essential personnel. Laboratories should begin immediately to preserve critical cell lines or mouse lines. Biological and chemical waste should be removed before interruptions caused by staff reductions.


  1. Remove and dispose of unnecessary items from your -80 and -20 freezers, and liquid nitrogen storage – In a crisis it may be necessary to consolidate perishable materials because of electricity failures that affect our freezers or no liquid nitrogen deliveries. Try to consolidate valuable material in freezers that are monitored and automatically notify you if the temperature is sub-optimal


  1. Map out the supply chains for your research – Assess your inventory and order reagents that have durable shelf lives. Attempt to establish an adequate inventory of important lab and safety supplies that may be in short supply due to global supply chain disruptions. Plan for delays or even loss of support in dry ice, liquid nitrogen, biological waste removal and hazardous substance removal.


  1. Check updates regularly from the EVPRI office – The EVPRI office is updating information about COVID19 and its impact on UofL. Their main COVID19 page is and their COVID19 FAQ page is


I greatly appreciate the many suggestions I’ve received about how to prepare our laboratories for these challenges. Please feel free to contact me with any questions about these guidelines.

I am confident we will get through the coming days and the lessons we learn will be useful in the years to come.


All the best,



Jon Klein, MD, PhD FASN

Vice-Dean for Research

James Graham Brown Foundation Endowed Chair in Proteomics

Director, Clinical and Translational Sciences Institute

University of Louisville School of Medicine

Mental health experts explain how sporting event cancellations affect athletes, fans

Mental health experts explain how sporting event cancellations affect athletes, fans

empty basketball court

The traditional thrill of March Madness in the basketball arena has given way to a new kind  of madness this season as novel coronavirus, or COVID-19, spreads. Conference tournaments, along with the NCAA Division I men’s and women’s 2020 basketball tournaments, are canceled because of the public health threat.

University of Louisville mental health experts say these cancellations make a big impact on both student athletes and fans.

UofL sports psychiatrist Christopher K. Peters, MD, says there will definitely be a grieving process for the student athlete.

“These students have and are working toward a high-level goal, which they may not be allowed to continue,” said Peters who is an associate professor of pediatrics at UofL and medical director of outpatient services with Norton Children’s Mental and Behavioral Health Center.

But, Peters points out, “perspective is everything and the grief should be tempered with the understanding that these decisions are made to mitigate a broader health crisis.”

Fans, too, feel the loss. UofL social psychologist Michael Cunningham, PhD, professor, Department of Communications, says fans have worked up to a major point on their calendars for these tournament events.

“People experience group identity and group affirmation as fans of a certain team – it is the gathering together of like-minded people who get a sense of personal validation and testosterone boost when their team wins,” Cunningham said. “It all adds spice to life and when it is taken away, life can be rather bland.”

Cunningham points out bracket fever and the entire support structure of tournament play will be pushed aside, as well.

“For some people it is like canceling Christmas,” he said.

Experienced administrator to lead emergency medicine at UofL, UofL Hospital

Experienced administrator to lead emergency medicine at UofL, UofL Hospital

Jeremy Thomas, M.D., M.B.A.

J. Jeremy Thomas, M.D., M.B.A., has joined the University of Louisville School of Medicine faculty as chair of the Department of Emergency Medicine. The UofL Board of Trustees approved his appointment during a regular meeting on Jan. 23. Thomas also will serve as chief of service for emergency medicine at UofL Hospital.

Thomas, board certified by the American Board of Emergency Medicine, was a tenured professor and executive vice chair of the University of Alabama-Birmingham Department of Emergency Medicine prior to his appointment at UofL. He also served as associate chief medical officer of emergency services and sepsis at UAB Medicine, UAB Hospital, as well as director of emergency services for UAB Hospital.

“The program at UofL has a very strong reputation for clinical training and for outstanding patient care. The resident teaching and the service to the community are outstanding,” Thomas said. “With my clinical operations and education background, the opportunity to lead this department was appealing.”

As chair of the UofL Department of Emergency Medicine, Thomas will oversee the training of medical students and residents within the School of Medicine. As chief of service for UofL Hospital, Thomas will direct clinical services provided by the emergency department.

School of Medicine Dean Toni Ganzel said she was pleased to recommend Thomas for the position.

“I am confident that Dr. Thomas’s talent, skills and energy will be a good fit for leading the department into the future and he will build on the many strengths of the department,” she said.

UofL Health CEO Tom Miller also expressed confidence in his selection.

“Dr. Thomas’s leadership complements the outstanding care provided every day by our emergency medicine team,” Miller said.

Thomas, an Alabama native, attended medical school at the University of South Alabama and earned a master’s of business administration from Auburn University. He completed his emergency medicine residency at UAB and a cardiovascular emergencies fellowship at the University of Virginia. He received a bachelor of science degree in biology from Cumberland College (now University of the Cumberlands) in Williamsburg, Ky.

“Having been to college in Kentucky and having colleagues and friends who trained at UofL and some who still live in the area made it an easy transition for me from a personal standpoint,” Thomas said.


University of Louisville, Norton Healthcare finalize pediatric integration

University of Louisville, Norton Healthcare finalize pediatric integration

UofL President Neeli Bendapudi, left, and UofL Pediatrics Chair Kimberly Boland, M.D., right.

The affiliation between Norton Healthcare, UofL Physicians – Pediatrics and the University of Louisville School of Medicine was finalized on Sunday, March 1, 2020.

Under the newly formed Norton Children’s Medical Group, affiliated with the UofL School of Medicine, 21 former UofL general pediatric and pediatric subspecialist practices are now part of Norton Healthcare. Approximately 600 providers and staff have transitioned with the affiliation.

“By integrating the best pediatric providers who are committed to providing safe, high-quality care, we will make it easier for families to access comprehensive medical care for their children,” said Russell F. Cox, president and CEO, Norton Healthcare.

The UofL physicians and providers who are currently on the faculty of the school of medicine will remain in their academic role and will also work clinically within Norton Children’s Medical Group.

“UofL is committed to helping nurture healthy children and communities while maintaining our strong academic training programs and research. This agreement ultimately will translate into even better care for children,” said Neeli Bendapudi, Ph.D., president, UofL.

“Integrating allows the two organizations to move forward, capitalizing on each other’s strengths for the benefit of our patients and families,” said Steven T. Hester, M.D., MBA, division president, provider operations, and system chief medical officer, Norton Healthcare.

The affiliation is designed to make it easier for patients to access outpatient care within the practices and inpatient care at Norton Children’s Hospital. Access will be improved through:

  • Scheduling enhancements
  • Recruiting additional providers
  • Increasing the number of multidisciplinary clinics, where patients with serious and chronic medical conditions can see multiple specialists on the same day
  • Using a single integrated electronic medical record, which will make it easier for patients and families to access test results and communicate with their providers

“Ultimately, the goal is to develop and deliver the best possible programs, services and patient experience for the children of Kentucky and beyond,” said Jennifer C. Evans, M.D., MPH, FACOG, system vice president, women’s and pediatric services, Norton Healthcare. “Both organizations have been committed to providing a seamless transition.”

This new model also will allow the practices to enhance their focus on providing highly skilled clinical care that is integrated with world-class medical education and research. A strong continued commitment to innovation and education is an important component of the integration. UofL’s academic and research mission is key to teaching the next generation of pediatric providers, which is essential to growing a regionally and nationally recognized pediatric program. In addition, by working together, the organizations can recruit, train and retain key talent for pediatric programs.

“Children will benefit from the strong academic training programs and research that will continue through the UofL School of Medicine,” said Kimberly A. Boland, M.D., professor and chair, department of pediatrics, University of Louisville School of Medicine. “Working together will help us attract additional specialists to Louisville to care for children with the most complex medical issues. We look forward to seeing what great things we can accomplish together, not only in clinical care, but also in educating future pediatricians and making new discoveries in the field of child and adolescent health care.”



Experts on aging to speak at statewide conference

UofL Trager Institute, Kentucky Association for Gerontology host Optimal Aging Conference
Experts on aging to speak at statewide conference

Optimal Aging Conference

With an emphasis on interdisciplinary approaches, the 2020 Optimal Aging Conference offers unique educational and networking opportunities for health care, social service and technology professionals, alongside older adults and their caregivers.

The conference, now in its fourth year, will feature experts in aging, dementia and Alzheimer’s research, innovation and public health. The University of Louisville Trager Institute and the Kentucky Association for Gerontology are hosting the conference April 19-21 at the Brown Hotel, 335 W. Broadway, in Louisville.

“We are thrilled to present such a strong line-up of speakers,” said Anna Faul, PhD, executive director of the University of Louisville Trager Institute. “The presenters, along with our breakout and poster sessions, will provide an incredibly rich and engaging experience for anyone working in the aging field or who has interest in inspiring our understanding of aging,” she said.

2020 Optimal Aging Conference Topics and Speakers:

Aging Inspired in Kentucky: Directions in Aging Policy (Panel Discussion)

  • Sandy Markwood, national CEO, National Association of Area Agencies on Aging
  • Eric Friedlander, acting secretary, Kentucky Cabinet for Health & Family Services
  • LaDonna Koebel, executive director, Office of Senior Protection & Mediation, Kentucky Office of the Attorney General

A Community Network Approach to Health
Eric Feigl-Ding, PhD
,chief health economist,MicroClinic International; faculty member, Harvard Medical School and Brigham and Women’s Hospital, Boston

Ending the Alzheimer's Pandemic
Dale Bredesen, MD
,professor, UCLA; founding president and professor emeritus, Buck Institute for Research on Aging; author of New York Times bestseller, The End of Alzheimer’s

 AARP Keynote: Words of Wisdom for #Agetech Entrepreneurs
Nigel Smith, MBA
, director, Hatchery Ventures, AARP Innovation Labs, Washington, D.C.

Alzheimer’s Update
Gregory Jicha, MD, PhD
, professor of neurology; director, Sanders-Brown Center on Aging at the University of Kentucky

Guided by the theme “Aging Inspired,” conference attendees also will hear from experts on a number of topics including: how to prevent financial elder abuse, national programs and arts activism counteracting ageism, programs for caregivers of persons with Alzheimer’s Disease and related dementias, the future impacts of artificial intelligence and robotics in senior care, trauma-informed care of older adults, international evidence-based falls programs, lifestyle medicine nutrition and more.

“The 2020 Optimal Aging Conference provides outstanding resources, inspiring ideas, and continuing education for Kentucky’s aging service professionals. The conference is a great opportunity for networking and professional development,” said Stacey Watkins, president of the Kentucky Association of Gerontology.

The UofL Trager Institute also will host a mobile workshop for its new Republic Bank Foundation Optimal Aging Clinic. The clinic, located in Louisville’s Innovation Corridor, is a one-stop-shop that provides integrated life-long wellness by combining lifestyle and preventative medicine with specialized and acute care.

Early-bird registration ends March 22. Learn more about registration, keynote speakers, and continuing education online at: Contact Natalie Pope at for more information.


From waterboy to star player: astrocytes shown to have a leading role in brain development

From waterboy to star player: astrocytes shown to have a leading role in brain development

William Guido, Ph.D., and Naomi Charalambakis, Ph.D.

Astrocytes, abundant, star-shaped glial cells in the central nervous system, are known to support neurons through such tasks as providing glue that helps neurons stick together, delivering nutrients and removing waste. However, research published last month in Proceedings of the National Academy of Sciences (PNAS) reveals they also play a commanding role in visual development.

University of Louisville researchers, working with colleagues at Virginia Tech Carillion (VTC), have discovered that astrocytes play a crucial role in directing interneurons, specialized neurons essential for vision, to the proper location in the brain during development. In response to visual stimulation, astrocytes express fibroblast growth factor 15, (FGF15), a molecule that directs the interneurons from germinal zones to their destination in the visual thalamus.

Neurobiologists William Guido, Ph.D., chair of the Department of Anatomical Sciences and Neurobiology at UofL, and Michael Fox, Ph.D., director of the Center for Neurobiology Research at Virginia Tech Carilion, worked in collaboration to reveal this process. The publication, “Retinal inputs signal astrocytes to recruit interneurons into visual thalamus,” also included significant lab work by graduate students at both universities.

“My lab identifies a neurocircuit and follows it during development to visualize it, manipulate it and understand how it works,” Guido said. “Dr. Fox provides the molecular mechanisms that underlie that circuit assembly. We combined our strengths to come up with these findings. Neither one of us could have done this on our own.”

Interneurons are part of a class of neurons that balance excitatory neurons and are essential in maintaining proper brain function. If the interneurons do not populate the thalamus correctly, neural circuits mediating vision do not develop properly. Therefore, the accuracy of the interneuron movement is essential for how the brain views the external world.

The proper balance between excitatory and inhibitory neurons is essential not only in visual processing, but in other brain functions as well. That means this research provides new targets for treating neurological diseases caused by an imbalance between inhibitory and excitatory activity in the brain.

“Neurological diseases such as epilepsy and schizophrenia can be attributed, in part, to abnormal interneuron levels and activity,” said Naomi Charalambakis, Ph.D., a UofL alumna who shares first authoriship of the publication. “This work not only reveals the importance of astrocytes in the development of thalamic interneuron circuitry, it also sparks more questions for future research: How does this affect the physiology patterns of other sensory systems? Does this phenotype manifest in behavioral differences?”

For this reason, Guido believes understanding how these cells migrate and are incorporated into brain circuitry could lead to new ways to ensure the proper balance of excitatory and inhibitory activity of other neurons.

“Knowing the importance of the location and incorporation of this type of neuron into the brain circuitry as well as the mechanism for its placement, we may be able to design strategies to make sure those neurons get where they should be or to overcome a deficit if they are missing,” Guido said. “This could allow us to correct some of these conditions.”

Another key finding of the work is that the astrocytes cue the migration of interneurons in response to external influences.

“Experience with the outside world is critical. When there is visual stimulation, that triggers the regulatory role for these cells in targeting,” Guido said.

Graduate students at both UofL and VTC conducted much of the lab work for this research. Charalambakis, whose 2018 doctoral dissertation resulted in this publication and another in The Journal of Neuroscience in May 2019, now is a senior science policy analyst at Federation of American Societies for Experimental Biology.

The synergistic research between the Guido and Fox labs has led to numerous discoveries of vital information about neurodevelopment and five high profile publications over the past decade. The National Eye Institute funds both research labs.

Robert Friedland, M.D., to conduct research on neurodegenerative disorders in Japan

Researcher awarded competitive fellowship grant from Japan Society for the Promotion of Science
Robert Friedland, M.D., to conduct research on neurodegenerative disorders in Japan

Robert Friedland, M.D.

University of Louisville neurologist and researcher Robert P. Friedland, M.D., a professor in the Department of Neurology, will teach and conduct research in Japan during a one-year sabbatical beginning May 1. Friedland will conduct research on neurodegenerative diseases at the Kyoto Prefectural University of Medicine (KPUM). The work is funded by a long-term Invitational Fellowship for Research in Japan from the Japan Society for the Promotion of Science (JSPS) which was awarded through a competitive selection process.

Friedland has studied Alzheimer’s disease, dementia and related conditions for more than 30 years. His previous work has uncovered the role of amyloid proteins made by intestinal and oral bacteria in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Alzheimer’s disease and Parkinson’s disease. Previously, Friedland worked with researchers at the National Cerebral and Cardiovascular Center in Osaka to reveal the important influence of oral bacteria on the development of hemorrhagic stroke.

In Kyoto, Friedland will further investigate the influence of the microbiota on neurodegenerative disease models in fruit flies. He plans tests to determine the influence of functional bacterial amyloid proteins on the aggregation of brain proteins, a key element of neurodegenerative diseases. Friedland will collaborate in this research with Toshiki Mizuno, Ph.D., of the KPUM Division of Neurology and Gerontology, one of several Japanese researchers with whom Friedland has worked for several decades.

He also will conduct research with collaborators at the Kyoto Institute of Technology.

“I am excited to have the opportunity to collaborate further with my Japanese colleagues and to conduct this research in Kyoto,” Friedland said.

JSPS awards fellowships to select international researchers to conduct collaborative work with researchers in Japan. Long-term fellowships for 2020 have been awarded in agriculture, engineering, chemistry, math, humanities and medicine. Friedland received one of four fellowships in the field of medicine.

After his year in Kyoto, Friedland will continue his research and clinical work at UofL, where his collaborators in the lab of Levi Beverly, Ph.D., currently are finishing data analysis on a study of the influence of bacterial amyloid on ALS in mice.

Pharmacology & Toxicology faculty honored by School of Medicine

Faculty from the Department of Pharmacology and Toxicology were honored at the inaugural School of Medicine Celebration of Faculty Excellence on February 18.

  • Dr. La Creis Kidd received the multicultural teaching award. 
  • Dr. Scott Whittemore received the Outstanding Scholarship, Research and Creative Activity Award for Career Achievement.
  • Dr. Christopher States was nominated for Outstanding Scholarship, Research and Creative Activity Award in the basic and applied sciences.



Owners of Holsopple Brewing talk beer at Beer with a Scientist Feb. 26

Owners of Holsopple Brewing talk beer at Beer with a Scientist Feb. 26

Sam Gambill and Kristy Holsopple

Flavors and aromas are the key to great beer. Kristy Holsopple and Sam Gambill have developed some uniquely flavored beers for their microbrewery, Holsopple Brewing, including brews flavored with blueberry, toasted hemp seeds and cinnamon, to name just a few.

Holsopple, a microbiologist, and Gambill met at a brewery and each have 15 years in the alcohol manufacturing industry. Now married with two young boys, they share their brewing talents with customers at the brewery. At the next Beer with a Scientist, Holsopple and Gambill will discuss beer sensory terms and how raw materials and yeast create beer aromas and flavor.

The talk begins at 7 p.m. on Wednesday, Feb. 26 at Holsopple Brewing, 8023 Catherine Lane. A 30-minute presentation will be followed by an informal Q&A session.

Admission is free. Purchase of beer or other items is not required but is encouraged. Organizers encourage Beer with a Scientist patrons to drink responsibly.

UofL cancer researcher Levi Beverly, Ph.D., created the Beer with a Scientist program in 2014 as a way to bring science to the public in an informal setting. At these events, the public is invited to enjoy exactly what the title promises:  beer and science.

Pfizer Inc. designates UofL first-of-its-kind Center of Excellence for epidemiological research

Pfizer Inc. designates UofL first-of-its-kind Center of Excellence for epidemiological research

Julio Ramirez, M.D., right, in the UofL infectious diseases laboratory

A new collaboration with Pfizer Inc. will enable the University of Louisville’s Division of Infectious Diseases to play a significant role in epidemiological research related to vaccine-preventable diseases affecting adults, including the elderly.

UofL has been designated the first Center of Excellence by Pfizer Vaccines.

“UofL’s Division of Infectious Diseases has a rich history of collaboration with Pfizer through the successful implementation of numerous clinical epidemiological research studies. We are excited to formalize a long-term collaboration that builds on these past successes,” said Julio Ramirez, M.D., chief of the Division of Infectious Diseases at the University of Louisville.

The Center of Excellence, directed by Ramirez, is a collaboration between the university and the pharmaceutical corporation aimed at determining the human health burden of important infectious diseases and potential vaccine effectiveness. The data will provide robust evidence to national health officials and independent policy makers who develop recommendations for the use of vaccines in immunization programs worldwide. Studies will take place in hospitals, long-term care facilities and the community.

UofL is the first Center of Excellence selected by Pfizer Vaccines Medical Development and Scientific/Clinical Affairs to be part of an international network of epidemiological research organizations. This designation is for a period of three years with an option for renewal. Pfizer selected UofL because of the university’s exceptional capabilities for conducting population-based surveillance and clinical research that engages multiple health care facilities, health care personnel, industry and communities-at-large.

“Pfizer has had an outstanding working relationship with the University of Louisville for more than 10 years,” said Luis Jodar, Ph.D., chief medical and scientific affairs officer, Pfizer Vaccines. “The quality of disease burden evidence varies widely worldwide. Deriving accurate and credible population-based incidence estimates require comprehensive surveillance to identify cases of diseases within a well-defined and well-characterized geographic area. Thanks to UofL’s excellent network of research partners, the population available for research studies in Louisville can provide the data to derive estimates of disease burden that can be generalized nationally.”

The demographics of Jefferson County, Kentucky, are similar to the United States in general, including racial and ethnic make-up, socioeconomic status, and the proportion of rural and urban populations.

The research studies conducted as part of the center may lead to economic growth and development for the city of Louisville and the Kentuckiana region, including jobs and educational opportunities in the health care industry.

“This collaboration will provide increased visibility for the university on a global scale, making UofL attractive for high-caliber researchers and research grants,” said Neeli Bendapudi, Ph.D., president of UofL. ”It also presents an exceptional opportunity for our researchers to improve the human condition by helping to reduce the burden of infectious diseases worldwide by generating data that will inform governments and health care policymakers.”

Pfizer studies anticipated for UofL include population-based surveillance of infectious diseases including Streptococcus pneumoniae, a bacteria which causes pneumonia and other infections, Clostridioides difficile, a bacteria that causes severe diarrhea and colitis, and respiratory syncytial virus (RSV), a common virus associated with mild cold-like symptoms but can cause severe infection in some people, including older adults. Visit for additional information on these diseases and two Center of Excellence studies already underway at UofL:

  • The City of Louisville Diarrhea (CLOUD) study launched in September 2019. Pfizer will be providing up to $6.5 million in funding for a one-year study of the incidence of diarrhea among Louisville-area residents.
  • The Louisville Pneumonia study is up to $4.5 million in funding provided by Pfizer for a one-year study of the incidence of pneumonia among adults in Louisville that launched in November 2019.

Watch a video here